{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Frio-bravo-qweek.simplecast.com%2Fepisodes%2Fepisode-215-meth-associated-hfref-JX59lKIF","width":444,"version":"1.0","type":"rich","title":"Episode 215: Meth-associated HFrEF","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/e7f25359-702b-47e8-97f2-d7f32a376648/89b65036-b2fa-4527-9fd4-f80317fd5fc8/rio_bravo_qweek_podcastlogonew.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/d7ff4740-8f7c-49da-8125-300ead5e03ed\" height=\"200\" width=\"100%\" title=\"Episode 215: Meth-associated HFrEF\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"Episode 215: Meth-associated HFrEF\n\nAbishak and Zat (medical students) explain the cardiotoxic effect of methamphetamine and the diagnosis and treatment of heart failure with reduced ejection fraction (HFrEF). Dr. Arreaza adds insight into the reversibility of meth-associated HFrEF.   \nWritten by Abishak Govindarajan, MSIV and Zat Akbar Shaw. American University of the Caribbean. Edits and comments by Hector Arreaza, MD. \n"}